Health

Menarini Group Presented Initial Safety and Efficacy Data from Phase 1b/2 ELEVATE and ELECTRA Combination Studies of ORSERDU® (Elacestrant) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2023 San Antonio Breast Cancer Symposium

The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, presented results from phase 1b/2 ELEVATE and ELECTRA clinical studies evaluating ORSERDU® (elacestrant) in combination with other treatments. Both the…

thaipr.net

13 ธ.ค. 66

Menarini Group Presents New Progression-Free Survival Data from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Clinically Relevant Subgroups of Patients with ER+, HER2- Metastatic Breast Cancer (mBC) with ESR1 Mutations at SABCS 2023

The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, today presented results from a new post hoc analysis of the pivotal EMERALD clinical study that demonstrated a clinically meaningful improvement in…

thaipr.net

12 ธ.ค. 66

Merck Collaborates with Acceleration Consortium on Open-Sourcing AI-Driven Experimentation Planner

Merck, a leading science and technology company, and the Acceleration Consortium, based at the University of Toronto, Canada, today jointly announced that their AI-driven experimentation planner Bayesian Back End (BayBE) is now available open-source on GitHub, with an unrestricted Apache 2.0 license. The joint open-source initiative combines the Merck portfolio of use cases with the Acceleration Consortium’s world-leading […]

thaipr.net

7 ธ.ค. 66
1 … 26 27 28 29 30 … 136

Copyright © 2026 Dataxet Limited (บริษัท ดาต้าเซ็ต จำกัด). All Rights Reserved.